Please assess the completion status of the following clinical trial:

Trial Title: Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Measurable disease~* Histologically confirmed adenocarcinoma of the colon or rectum~* K-ras wild type based on either primary or metastatic tumor~* Must have received prior first-line therapy comprising oxaliplatin-based fluoropyrimidine-containing chemotherapy and bevacizumab for metastatic colorectal cancer~* Registration within 42 days since confirmed disease progression~* Performance status 0-1~* ANC ≥ 1,500/μL~* Platelet count ≥ 75,000/μL~* Hemoglobin ≥ 9 g/dL~* Serum creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance ≥ 40 mL/min~* Urine protein ≤ 1+ on dipstick or routine urinalysis (if ≥ 2+, a 24-hour urine collection must demonstrate \< 1,000 mg of protein)~* Total bilirubin ≤ 2.0 mg/dL~* AST and ALT ≤ 3.0 times ULN (5.0 times ULN for patients with liver metastases)~* INR ≤ 1.6 (≤ 3.0 for patients on warfarin and no active bleeding \[i.e., no bleeding within the past 14 days\])~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study therapy~* At least 28 days and no more than 90 days since prior bevacizumab~* Concurrent stable dose of oral anticoagulant or low-molecular weight heparin allowed~Exclusion Criteria:~* Brain or CNS metastases~* Pregnant or nursing~* Prior therapy with drugs other than oxaliplatin and a fluoropyrimidine plus bevacizumab for colorectal cancer~* Clinically significant (equivalent to NCI CTCAE grade 3-4) bleeding episodes within the past 3 months~* Active infection~* Symptomatic congestive heart failure~* Unstable angina pectoris~* Symptomatic or poorly controlled cardiac arrhythmia~* Uncontrolled thrombotic or hemorrhagic disorder~* Uncontrolled or poorly controlled hypertension despite standard medical management (e.g., consistently systolic BP \> 160 mm Hg and diastolic BP \> 90 mm Hg)~* Acute arterial thrombotic events within the past 6 months, including cerebrovascular accident, transient ischemic attack, myocardial infarction, or unstable angina~* Other cancer requiring therapy within the past 3 years except in situ carcinoma or nonmelanoma skin cancer~* Acute or subacute intestinal obstruction~* History of inflammatory bowel disease requiring pharmacological and/or surgical intervention within the past 12 months~* Known allergy to any of the treatment components~* Major surgery within the past 28 days~* Subcutaneous venous access device placement within the past 7 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (IC) (Type: ACTIVE_COMPARATOR): Patients receive cetuximab (500 mg/m2) intravenously (IV) over 60-120 minutes and irinotecan hydrochloride (180 mg/m2) over 60-90 minutes on day 1. Treatment repeats every 2 weeks until disease progression or unacceptable toxicities.
- Arm B (ICR) (Type: EXPERIMENTAL): Patients receive ramucirumab (8 mg/kg) IV over 60 minutes on day 1 and cetuximab and irinotecan hydrochloride as in arm A. Treatment repeats every 2 weeks until disease progression or unacceptable toxicities.
- Arm C (mICR) (Type: EXPERIMENTAL): Patients receive reduced dose of ramucirumab (6 mg/kg) IV over 60 minutes on day 1 and cetuximab (150 mg/m2) and irinotecan hydrochloride (400 mg/m2) as in arm B. Treatment repeats every 2 weeks until disease progression or unacceptable toxicities.

Based on this trial design, predict the completion outcome and termination type (if applicable).